Prospects for cannabinoid therapies in basal ganglia disorders

Cannabinoids and Parkinsons Disease

(2012) Moises Garcia-Arencibia et al.   CNS & Neurological Disorders-Drug Targets

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease

(2011) C García et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

(2011) Onintza Sagredo et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

(2010) Cristina Blázquez et al.   BRAIN

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat

(2010) Sinéad Walsh et al.   BRAIN RESEARCH BULLETIN

Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease

(2010) EL Scotter et al.   BRITISH JOURNAL OF PHARMACOLOGY

Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats

(2010) Harikesh Kalonia et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription

(2010) Marcus J. Calkins et al.   EXPERIMENTAL NEUROLOGY

The endocannabinoid system as a target for the treatment of neuronal damage

(2010) Javier Fernández-Ruiz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Inflammation in neurodegenerative diseases

(2010) Sandra Amor et al.   IMMUNOLOGY

Evidence that MDMA (‘ecstasy’) increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain

(2010) Elisa Torres et al.   JOURNAL OF NEUROCHEMISTRY

Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo

(2010) K. Van Laere et al.   JOURNAL OF NUCLEAR MEDICINE

Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis

(2010) José L Lanciego et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Microglial activation and chronic neurodegeneration

(2010) Melinda E. Lull et al.   Neurotherapeutics

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

(2010) R. G. Pertwee et al.   PHARMACOLOGICAL REVIEWS

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

(2010) Chiara Zuccato et al.   PHYSIOLOGICAL REVIEWS

Evidence for a Role of Endocannabinoids, Astrocytes and p38 Phosphorylation in the Resolution of Postoperative Pain

(2010) Matthew S. Alkaitis et al.   PLoS One

Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury

(2009) Alfonso Romero-Sandoval et al.   ANESTHESIOLOGY

The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease

(2009) J.E. Kelsey et al.   BEHAVIOURAL BRAIN RESEARCH

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

(2009) Javier Palazuelos et al.   BRAIN

Neuroglia in neurodegeneration

(2009) Michael T. Heneka et al.   BRAIN RESEARCH REVIEWS

The endocannabinoid system as a target for the treatment of motor dysfunction

(2009) Javier Fernández-Ruiz   BRITISH JOURNAL OF PHARMACOLOGY

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

(2009) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2009) David A. Price et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

(2009) David R Janero et al.   EXPERT OPINION ON EMERGING DRUGS

Anandamide enhances IL-10 production in activated microglia by targeting CB2receptors: Roles of ERK1/2, JNK, and NF-κB

(2009) Fernando Correa et al.   GLIA

Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

(2009) Onintza Sagredo et al.   GLIA

Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid

(2009) Ricardo Lagoa et al.   JOURNAL OF NEUROCHEMISTRY

Combination therapy with Coenzyme Q10and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

(2009) Lichuan Yang et al.   JOURNAL OF NEUROCHEMISTRY

Neuroinflammation in Parkinson’s Disease

(2009) Jae-Kyung Lee et al.   Journal of Neuroimmune Pharmacology

Selective CB2 Receptor Agonism Protects Central Neurons from Remote Axotomy-Induced Apoptosis through the PI3K/Akt Pathway

(2009) M. T. Viscomi et al.   JOURNAL OF NEUROSCIENCE

A pilot study using nabilone for symptomatic treatment in Huntington's disease

(2009) Adrienne Curtis et al.   MOVEMENT DISORDERS

Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors

(2009) Sandra Pérez-Rial et al.   NEUROBIOLOGY OF AGING

1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice

(2009) L. Luongo et al.   NEUROBIOLOGY OF DISEASE

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease

(2009) M.J. Dowie et al.   NEUROSCIENCE

The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

(2009) Vincenzo Di Marzo   PHARMACOLOGICAL RESEARCH

Endocannabinoid-Mediated Control of Synaptic Transmission

(2009) Masanobu Kano et al.   PHYSIOLOGICAL REVIEWS

The Endocannabinoid System in Huntingtons Disease

(2008) M. Pazos et al.   CURRENT PHARMACEUTICAL DESIGN

Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide

(2008) Frida Loría et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

The CB2Cannabinoid Receptor Controls Myeloid Progenitor Trafficking

(2008) Javier Palazuelos et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the endocannabinoid system: to enhance or reduce?

(2008) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

Endocannabinoid signaling in microglial cells

(2008) Nephi Stella   NEUROPHARMACOLOGY

Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury

(2008) M. Zhang et al.   NEUROSCIENCE

Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid–linked events in Down’s syndrome

(2008) E. Núñez et al.   NEUROSCIENCE

The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson's disease

(2008) M. Jimenez-Del-Rio et al.   NEUROSCIENCE RESEARCH

Cannabinoid CB2receptors in human brain inflammation

(2007) C Benito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression

(2007) G Esposito et al.   BRITISH JOURNAL OF PHARMACOLOGY